Leerink Partners started coverage on ANI Pharmaceuticals shares.
3 reports, 2 independent
Updated Nov 1
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink Partners started coverage on ANI Pharmaceuticals shares.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.CEO stock sale disclosed for ANI Pharmaceuticals.1 source
Market activity around ANI Pharmaceuticals includes analyst rating issuance and increased buying from Amundi and WINTON GROUP.1 source
Leerink Partners started coverage on ANI Pharmaceuticals shares.1 source
Keep exploring
The entities involved
-
Leerink partners
U.S. investment bank
Nothing else this week.
Related events
- Leerink Partners provided coverage and price targets for Freenome on September 26, 2026.
- Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
- Leerink Partners began coverage on Shattuck Labs shares, and TD Cowen subsequently raised the shares to a strong-buy rating.
- Illumina and Leerink partners are involved in a new development.
- Leerink Partners cut its shares rating for Akebia Therapeutics on November 3, 2026.